NCT06788639 is a clinical trial of Lisocabtagene maraleucel in Chronic Lymphocytic Leukemia (CLL), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

Who is sponsoring NCT06788639?

NCT06788639 is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

What drugs are being tested in NCT06788639?

Interventions in NCT06788639: Lisocabtagene maraleucel.

What condition does NCT06788639 study?

NCT06788639 studies Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).

Is NCT06788639 still recruiting?

NCT06788639 is currently recruiting now. Last updated 24 February 2025.

Last reviewed 2025-02-24 · How we verify

NCT06788639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Recruiting now Last updated 24 February 2025

What this trial tests

trial testing Lisocabtagene maraleucel in Chronic Lymphocytic Leukemia (CLL) in 300 participants. Currently enrolling.

Timeline

4 February 2025

Primary endpoint
30 June 2044

30 June 2044

Quick facts

Lead sponsor	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	4 February 2025
Primary completion	30 June 2044
Estimated completion	30 June 2044
Sites	1 location across United States

Drugs / interventions tested

Lisocabtagene maraleucel (LISOCABTAGENE MARALEUCEL) — full drug profile →

Conditions studied

Chronic Lymphocytic Leukemia (CLL) — all drugs for Chronic Lymphocytic Leukemia (CLL) →
Small Lymphocytic Lymphoma (SLL) — all drugs for Small Lymphocytic Lymphoma (SLL) →

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lisocabtagene maraleucel

Trials testing the same drug.

NCT06788652 — A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Mark · recruiting
NCT06794268 — A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the · recruiting
NCT06357754 — Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod · recruiting

Other recruiting trials for Chronic Lymphocytic Leukemia (CLL)

Currently open trials in the same condition.

NCT07428707 — Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib · EARLY_PHASE1 · recruiting
NCT07205315 — A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p · EARLY_PHASE1 · recruiting
NCT05908409 — A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT05724121 — Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax · recruiting
NCT04758975 — Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na · Phase 2 · recruiting

Other Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials

Trials by the same sponsor.

NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT07015242 — A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplan · Phase 2 · recruiting
NCT07115745 — A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease · Phase 1 · recruiting
NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
NCT06615479 — A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06788639 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Last refreshed: 24 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing